Ro vs Henry Meds: Multi-Vertical Incumbent vs Cohort-Cheapest Specialist

Who wins for each use case

We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.

• Insurance pathway for branded GLP-1

  Winner: Ro

  Ro runs a mature insurance concierge for branded Wegovy and Zepbound that can drop effective monthly cost to $0-$25 for users with eligible commercial coverage and a manufacturer savings card. Henry Meds is built around cash-pay compounded medication and does not run a comparable branded-insurance pathway. For any insured user, this row decides the comparison.

• BBB rating and complaint posture

  Winner: Ro

  Ro is BBB Accredited with a B rating since July 2018, the longest BBB tenure in our compounded cohort. Henry Meds is NOT BBB-accredited and carries an F letter grade with 192 complaints in three years (25 of which received no business response). The non-response rate is what drives the F. This is the largest single trust gap in our cohort.

• Trustpilot signal credibility

  Winner: Ro

  Henry Meds shows 4.5/5 across roughly 12,300 reviews on Trustpilot, but the page itself carries Trustpilot's suspected-fraudulent-review notice. We weight that fraud flag more heavily than the headline number. Ro's Trustpilot is 3.7/5 across roughly 3,200 reviews with no fraud notice. Ro's lower headline rating is more credible than Henry Meds's higher but flagged sample.

• Manufacturer lawsuit posture

  Winner: Ro

  Henry Meds has an active Eli Lilly lawsuit (4:25-cv-03536, N.D. Cal.) over compounded-tirzepatide marketing claims. The personalization-marketing claim survived a September 2025 partial dismissal, so the case is moving forward. Ro has no comparable open manufacturer litigation. The lawsuit is about marketing rather than product safety, but it is ongoing legal pressure rather than a closed chapter.

• Multi-vertical platform breadth

  Winner: Ro

  Ro covers weight loss, men's health, hair loss, fertility, and skincare under one membership model with operations going back to 2017. Henry Meds is GLP-1-focused (compounded only) with a narrower product line. If you want one provider for multiple needs, Ro is the obviously broader option.

• Cash-pay price on oral semaglutide

  Winner: Henry Meds

  Henry Meds starts oral semaglutide around $99/month, materially below Ro's compounded pricing structure. If pure headline price is the only thing you weight, Henry Meds is the cheapest option that exists. The caveat: BBB complaints describe a secondary $49/month subscription disclosed only in the terms of service, so the all-in monthly cost can be higher than the headline. With that caveat acknowledged, Henry Meds wins this row.

• Oral tirzepatide tablet availability

  Winner: Henry Meds

  Henry Meds offers oral tirzepatide tablets at $349/month month-to-month or $234/month on annual prepay, a relatively rare product line. Ro does not carry oral tirzepatide tablets at comparable price. If you specifically want oral tirzepatide, the choice narrows to Henry Meds.

• Cancellation friction

  Winner: Ro

  Henry Meds requires a phone call to cancel; multiple BBB complaints describe a pattern of unanswered calls and continued billing after attempted cancellation. Ro provides a documented in-app cancellation flow without comparable complaint volume. Both have cancellation complaints in their BBB records, but Henry Meds's phone-only-with-unanswered-calls pattern is meaningfully worse.

Pricing in plain terms

Ro: $45 first month, $145/month standard or $74/month annual prepay, plus medication. With eligible commercial insurance and a Novo Nordisk savings card, branded Wegovy via Ro can drop to $0-$25/month effective cost. Without insurance, cash-pay compounded GLP-1 through Ro lands at $200-$400/month medication on top of membership. Henry Meds: $99/month oral semaglutide, $149-$179/month injectable semaglutide, $349/month oral tirzepatide tablets, $449/month injectable tirzepatide, plus the BBB-flagged secondary $49/month subscription. The simplest decision rule: if you have insurance covering Wegovy or Zepbound, Ro is the right answer; if you are cash-pay and weight trust signals at all, Ro is still the right answer; if you are cash-pay with pure-price as the binding constraint AND want a Henry Meds-specific product line (oral tirzepatide), Henry Meds is the option that exists, but go in eyes wide open.